PharmaEssentia USA Corporation, a leading biopharmaceutical company, is headquartered in the United States and operates primarily in the North American market. Founded in 2003, the company has made significant strides in the development of innovative therapies, particularly in the field of rare diseases and blood disorders. PharmaEssentia is renowned for its flagship product, which offers unique treatment options that address unmet medical needs. The company’s commitment to research and development has positioned it as a key player in the biopharmaceutical industry, with notable achievements in clinical trials and regulatory approvals. With a focus on patient-centric solutions, PharmaEssentia continues to advance its mission of improving health outcomes and enhancing the quality of life for patients worldwide.
How does PharmaEssentia USA Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PharmaEssentia USA Corporation's score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PharmaEssentia USA Corporation, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of PharmaEssentia Corporation, which may influence its climate commitments and reporting practices. As of now, PharmaEssentia USA Corporation has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). Additionally, there are no climate pledges or initiatives reported that would indicate a proactive stance towards reducing carbon emissions. Given the lack of specific emissions data and reduction initiatives, it is essential to consider the broader context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon footprint reduction. Companies within this sector are often encouraged to adopt comprehensive climate strategies to align with global climate goals. In summary, while PharmaEssentia USA Corporation does not currently provide emissions data or specific climate commitments, its affiliation with PharmaEssentia Corporation may play a role in shaping its future sustainability efforts.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 707,230 | 000,000 | 000,000 | 000,000 | 000,000 | 
| Scope 2 | 3,055,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 3 | 1,492,660 | 000,000 | 000,000 | 000,000 | 000,000 | 
PharmaEssentia USA Corporation's Scope 3 emissions, which decreased by 84% last year and decreased by approximately 93% since 2019, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 3% of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
PharmaEssentia USA Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.